Bank of America
NEUP

Bank of America’s Neuphoria Therapeutics NEUP Stock Holding History

Bank of America’s Portfolio NEUP Stock Details NEUP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-18
Closed -$70 – 7138
2025
Q4 		$70 Buy
18
+1
+6% +$7 ﹤0.01% 6896
2025
Q3 		$201 Buy
17
+16
+1,600% +$149 ﹤0.01% 7731
2025
Q2 		$7 Buy
+1
New +$6 ﹤0.01% 8313
2025
Q1 		– Sell
-6,484
Closed -$22.2K – 8640
2024
Q4 		$22.2K Buy
+6,484
New +$22.9K ﹤0.01% 6830

Other funds holding NEUP

LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
SC
Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Bank of America's NEUP Position: Q1 2026 in Review

Bank of America sold out of Neuphoria Therapeutics (NEUP) in Q1 2026, closing a stake of 18 shares — an estimated $70 sold.

Bank of America first reported a position in NEUP in Q4 2024 and held it in 4 quarters. The position peaked at $22.2K in Q4 2024. 19 funds tracked by Wall St. Rank hold NEUP as of Q1 2026.

  • Bank of America reported no remaining Neuphoria Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Bank of America sold 18 Neuphoria Therapeutics shares in Q1 2026, an estimated $70.
  • Bank of America first reported a position in Neuphoria Therapeutics in Q4 2024 and held it in 4 quarters.
  • Bank of America's Neuphoria Therapeutics position peaked at $22.2K in Q4 2024.
  • 19 funds tracked by Wall St. Rank held Neuphoria Therapeutics as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.